Arbutus Biopharma Corporation is a clinical stage biopharmaceutical company focused on infectious disease. It is developing imdusiran (AB-729) a GalNAc conjugated subcutaneously delivered RNAi therapeutic and an oral inhibitor of PD L1 for the treatment of chronic hepatitis B. The company also protects and defends its lipid nanoparticle technology which is used in certain mRNA vaccines and is involved in litigation to obtain compensation for unauthorized use of that technology.

Revenue is generated through licensing agreements royalty streams milestone payments and settlement proceeds. The company received an upfront cash payment of forty million dollars from Qilu Pharmaceutical Co Ltd for a license to develop and commercialize imdusiran in Greater China and Taiwan and is eligible for additional milestone payments up to two hundred forty five million dollars and double digit royalties on sales in that region. Arbutus receives tiered royalties on global net sales of Alnylam’s ONPATTRO product and a second royalty interest from Acuitas Therapeutics Inc. It also stands to receive a share of the noncontingent settlement payment of nine hundred fifty million dollars and a contingent payment up to one point three billion dollars from Moderna under a settlement agreement concerning lipid nanoparticle patent rights. Additionally the company holds an equity interest in Genevant Sciences Ltd and may benefit from future distributions.

Arbutus Biopharma Corporation operates in the competitive field of hepatitis B therapeutics where it faces large pharmaceutical companies such as GSK plc Gilead Sciences Inc Assembly Biosciences Inc Aligos Therapeutics Inc AusperBio Therapeutics Inc Brii Biosciences Limited Mirum Pharmaceuticals Inc and Precision Biosciences Inc. The company’s competitive advantage lies in its proprietary lipid nanoparticle platform its GalNAc conjugated RNAi therapeutic imdusiran and its oral PD L1 inhibitor which together target multiple steps of the hepatitis B virus life cycle. Its strong patent portfolio and ongoing litigation over lipid nanoparticle use provide additional leverage.

The company serves patients diagnosed with chronic hepatitis B and the healthcare providers that treat them. Its collaboration partners include Qilu Pharmaceutical Co Ltd Alnylam Pharmaceuticals Inc Acuitas Therapeutics Inc and Genevant Sciences Ltd. These relationships provide access to markets in Greater China Taiwan and global royalty streams.